FDA label d38649ac-b894-4b80-9cf3-b88b2c7a9e8b
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- afc9d7a5-40bc-45dc-81a7-b30f799f5e95
- SPL ID
- d38649ac-b894-4b80-9cf3-b88b2c7a9e8b
- Version
- 3
- Effective date
- 2011-01-03
- Source export date
- 2026-10-12
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/edd23646015c9adc800cdbe2b778398a2d2b70e90dce5721ef2b191499a0397f/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 02:49:19
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | d38649ac-b894-4b80-9cf3-b88b2c7a9e8b | id | |
| spl set id | afc9d7a5-40bc-45dc-81a7-b30f799f5e95 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS AND PRECAUTIONS General In rare instances severe allergic reactions and anaphylaxis have been reported with the use of colchicine. Most of these rare allergic reactions have been reported to occur within several hours after readministration following prior usage of the drug. The appearance of hypersensitivity reactions requires cessation of therapy with colchicine. Both accidental and intentional overdoses with colchicine in children and adults have been reported [See OVERDOSE (10)]. Keep Colchicine Tablets out of the reach of children. Renal Impairment Colchicine is significantly excreted in urine in healthy subjects. Clearance of Colchicine is decreased in patients with impaired renal function. Consideration should be given to the reduction of the dosage in patients with renal impairment. Patients with any degree of renal dysfunction, who are treated with Colchicine, should be monitored closely for adverse effects of Colchicine. Hepatic Impairment The clearance of Colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment, compared to healthy subjects. Consideration should be given to the reduction of the dosage in patients with hepatic impairment. All patients with hepatic impairment should be monitored closely for adverse effects of Colchicine.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The most frequent adverse effects of oral colchicine in therapeutic doses are those involving the gastrointestinal tract with diarrhea, nausea, vomiting, and abdominal pain often being the first signs of toxicity and the first indication that the colchicine dose may need to be reduced or therapy stopped. Larger doses may cause profuse diarrhea, gastrointestinal hemorrhage, skin rashes, renal and hepatic damage. Bone marrow suppression with agranulocytosis, thrombocytopenia, and aplastic anemia have rarely occurred with prolonged treatment, as have peripheral neuropathy, myopathy, rashes, and alopecia. Side effects due to Colchicine appear to be a function of dosage. The possibility of increased colchicine toxicity in the presence of renal or hepatic dysfunction should be considered.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.